AU2010294292B2 - Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer - Google Patents

Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer Download PDF

Info

Publication number
AU2010294292B2
AU2010294292B2 AU2010294292A AU2010294292A AU2010294292B2 AU 2010294292 B2 AU2010294292 B2 AU 2010294292B2 AU 2010294292 A AU2010294292 A AU 2010294292A AU 2010294292 A AU2010294292 A AU 2010294292A AU 2010294292 B2 AU2010294292 B2 AU 2010294292B2
Authority
AU
Australia
Prior art keywords
alkyl
benzenesulfonamide
methyl
butan
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010294292A
Other languages
English (en)
Other versions
AU2010294292A1 (en
Inventor
Karen Miller-Moslin
Bakary-Barry Toure
Michael Scott Visser
Naeem Yusuff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010294292A1 publication Critical patent/AU2010294292A1/en
Application granted granted Critical
Publication of AU2010294292B2 publication Critical patent/AU2010294292B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
AU2010294292A 2009-09-10 2010-09-08 Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer Ceased AU2010294292B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24125109P 2009-09-10 2009-09-10
US61/241,251 2009-09-10
PCT/EP2010/063169 WO2011029842A1 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2010294292A1 AU2010294292A1 (en) 2012-03-01
AU2010294292B2 true AU2010294292B2 (en) 2013-07-18

Family

ID=43016684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010294292A Ceased AU2010294292B2 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer

Country Status (12)

Country Link
US (1) US8809352B2 (enExample)
EP (1) EP2475661B1 (enExample)
JP (1) JP2013504536A (enExample)
KR (1) KR20120078715A (enExample)
CN (1) CN102498111A (enExample)
AU (1) AU2010294292B2 (enExample)
BR (1) BR112012005343A2 (enExample)
CA (1) CA2772989A1 (enExample)
EA (1) EA020586B1 (enExample)
ES (1) ES2443845T3 (enExample)
MX (1) MX2012003007A (enExample)
WO (1) WO2011029842A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
KR101823488B1 (ko) 2013-10-14 2018-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CA2990477A1 (en) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
AU2017206731A1 (en) * 2016-01-11 2018-08-02 Merrimack Pharmaceuticals, Inc. Inhibiting B-cell lymphoma 2 (Bcl-2) and related proteins
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
EP4538273A1 (en) * 2022-06-10 2025-04-16 Hitgen Inc. Compound and use thereof in preparation of bcl-xl inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061208A2 (en) * 2006-11-15 2008-05-22 Genentech, Inc. Arylsulfonamide compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ATE372330T1 (de) * 2002-03-21 2007-09-15 Abbott Lab N-sulfonylurea-apoptosis-förderer
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗－细胞凋亡bcl－2家族成员的小分子抑制剂及其应用
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061208A2 (en) * 2006-11-15 2008-05-22 Genentech, Inc. Arylsulfonamide compounds

Also Published As

Publication number Publication date
EA020586B1 (ru) 2014-12-30
EP2475661A1 (en) 2012-07-18
ES2443845T3 (es) 2014-02-20
AU2010294292A1 (en) 2012-03-01
JP2013504536A (ja) 2013-02-07
EP2475661B1 (en) 2013-10-23
WO2011029842A1 (en) 2011-03-17
MX2012003007A (es) 2012-04-11
CN102498111A (zh) 2012-06-13
EA201200472A1 (ru) 2012-10-30
BR112012005343A2 (pt) 2016-03-22
US8809352B2 (en) 2014-08-19
US20120165298A1 (en) 2012-06-28
KR20120078715A (ko) 2012-07-10
CA2772989A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
AU2010294292A1 (en) Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
JP6983273B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
TWI923944B (zh) 嗒基-噻唑甲醯胺化合物
JP7073359B2 (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
KR102429220B1 (ko) 치환 4-페닐피페리딘, 그 제조 및 사용
AU2017208998B2 (en) Bruton's tyrosine kinase inhibitors
TWI914378B (zh) 作為ａｌｋ５抑制劑之嗒𠯤基胺基衍生物
TW201823249A (zh) Ｍｅｎｉｎ－ｍｌｌ相互作用之稠合二環抑制劑
ES2734268T3 (es) Derivados de urea y amida de aminoalquilpiperazinas y uso de los mismos
TW201350476A (zh) 用於調節表皮生長因子受體（ｅｇｆｒ）活性之化合物及組合物
BR112013002182B1 (pt) Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos
KR20200028423A (ko) Rock의 억제제로서의 5-원 및 비시클릭 헤테로시클릭 아미드
KR20230175222A (ko) Nek7 억제제
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
AU2009318855A1 (en) Lactams as beta secretase inhibitors
KR20240013134A (ko) 시그마 리간드로서 피리딘-술폰아미드 유도체
US20170240514A1 (en) Small Molecule Agonists of Neurotensin Receptor 1
JP7142010B2 (ja) メニン－ｍｌｌ相互作用のアゼパン阻害剤
TW202602878A (zh) Ａｋｔ１調節劑
WO2020257527A1 (en) Compounds for inhibiting fgfr4
US20100278833A1 (en) Thiophene-imidazopyridines
CN117597346A (zh) Nek7抑制剂
WO2015016195A1 (ja) Ｗｎｔシグナル阻害剤
TWI912370B (zh) 芳香雜環類化合物、藥物組合物及其應用
WO2019106368A1 (en) Pyrrolo[3,2-c]pyridin-4-one derivatives as pfk inhibitors useful for the treatment of protozoal infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired